



Name : Mrs. Shivangi

Address: 44A Kalkaji ext

INDIA OP AGREEMENT

Plan

: ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN

Age: 32 Y

Sex: F

OP Number: SCHIOPV23380 Bill No: SCHI-OCR-8685

UHID:SCHI.0000016430

no Serive Type/ServiceName	Department
	LTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324
1 URINE GLUCOSE(FASTING)	
2 GAMMA GLUTAMYL TRANFERASE (GGT)	
3 HbA1c, GLYCATED HEMOGLOBIN	
42 D ECHO 1 D NO	+ willing
5 LIVER FUNCTION TEST (LFT)	7 7/1/1/0
6 X-RAY CHEST PA	
7 GLUCOSE, FASTING	
8 HEMOGRAM + PERIPHERAL SMEAR —	
9 ENT CONSULTATION \	
10 FITNESS BY GENERAL PHYSICIAN	
11 GYNAECOLOGY CONSULTATION	
12 DIET CONSULTATION	
13 COMPLETE URINE EXAMINATION —	
14 URINE GLUCOSE(POST PRANDIAL)	
15 PERIPHERAL SMEAR	
16 ECG V	
17 BLOOD GROUP ABO AND RH FACTOR	
18 LIPID PROFILE	
19 BODY MASS INDEX (BMI)	
20 LBC PAP TEST- PAPSURE	
21 OPTHAL BY GENERAL PHYSICIAN	
22 RENAL PROFILE/RENAL FUNCTION TEST (RF)	T/KFT)
23 ULTRASOUND - WHOLE ABDOMEN	
24 THYROID PROFILE (TOTAL T3, TOTAL T4, TSF	H)
25 DENTAL CONSULTATION	
26 GLUCOSE, POST PRANDIAL (PP), 2 HOURS (PO	OST MEAL)

PHC Desk

From: Sent: noreply@apolloclinics.info 23 November 2023 15:10

To:

aditya.sharma7@bankofbaroda.co.in

Cc:

phc.klc@apollospectra.com; syamsunder.m@apollohl.com;

cc.klc@apollospectra.com

Subject:

Your Apollo order has been confirmed



Dear shivangi sharma .,

Namaste Team.

Greetings from Apollo Clinics,

With regards to the below request the below appointment is scheduled at SPECTRA NEHRU ENCLAVE clinic on 2023-11-27 at 09:30-09:45.

Payment Mode	Credit
Corporate Name	ARCOFEMI HEALTHCARE LIMITED
Agreement Name	ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN INDIA OP AGREEMENT
Package Name	[ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324]

"As stated in the agreement terms, kindly carry all relevant documents such as HR Authorization Letter, Appointment Confirmation Mail, valid government ID proof, company ID card etc. along with you."

Note: Video recording or taking photos inside the clinic premises or during camps is not allowed and would attract legal consequences.

Note: Also once appointment is booked, based on availability of doctors at clinics tests will happen, any pending test will happen based on doctor availability and clinics will be updating the same to customers.



SIIRA REGIT GOVERNMENT OF INDIA



शिंवागी Shivangi जन्म वर्ष / Year of Birth : 1991 महिला / Female



2513 4553 8498



भारतीय विशिष्ट गृहचान प्राधिकरण UNIQUE IDENTIFICATION AUTHORITY OF INDIA

पता: D/O सुनंद कुमार, हाउस न २२१ वार्ड न ४ रौडा सेक्टर तहसील सदर, बिलासपुर, हिमाचल प्रदेश, 174001

Address: D/O Sunand Kumar, HOUSE NO 221 WARD NO 4 ROURA SECTOR TEHSIL SADAR, Bilaspur (209), Bilaspur, Bilaspur, Himachal Pradesh, 174001

MADADAY

Dr. Lalit Mohan Parashar
MS (ENT)
Ear, Nose, Throat Specialist and
Head & Neck Surgeon

For Appointment: +91 11 40465555
Mob.: +91 9910995018
MCI No. 4774/85

Snivaval
32/



TO NO LEADING TENT PROBLEM

0/2-

NOSIZ - MILD PUINITIS à DNS

Town - NA

Estes - BL In D

Voice, Sparin NO MASAINE (N)

If IN Norman

An MONDESLOR 161

XII

27/11/2020

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com



Mr- Shivang i



All two coop - of c

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

27/11/2023



Mers. Shivangi 32 Years / Female.

C/C!- Regular Devita Unch - 4p.

PDH! RCT in sypper left back eigen in the year 2018, followed by

O/E!- Calculus +.

faulty Rest lusthisis 6.

Calcions met

Occlusal Buccal Carios Prt

Advised! - : Sealing . Ristoration

8.7 6

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Spectra
HOSPITALS
Specialists in Surgery

LMP-2/11/23.

PH - W

breasts (W)

PIA (V)

Internal examination

sot dans .

LBC taken


Janus 1

8 hivanj. 32y | 1= 27/11/23 bre.

- Lactacyd wash daily.

- Inj Gardanil - 4 (0,2,6) mm 1/M.

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com





NAME:	SHIVANGI	AGE/SEX	32	YRS/ F
UHID:	16430			
REF BY :	APOLLO SPECTRA	DATE:-	27.11	2023

ULTRASOUND WHOLE ABDOMEN

Liver: Appears normal in size, and echotexture. Intrahepatic biliary radicles are not dilated. No focal or diffuse lesion is seen. CBD and portal vein are normal in caliber.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

Both Kidneys: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

Urinary Bladder: is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Uterus is antiverted and normal in size. It measures 7.6 x 4 cm. Outline is smooth. Myometrium is normal. Endometrial echoes are normal and measures 6.9 mm

Both ovaries are normal in size, shape and echotexture.

Right ovary: 3.1 x 1.5 cm Left ovary: 2.7 x 1.5 cm

No obvious adenexal mass is seen. No free fluid seen.

IMPRESSION: NO SIGNIFICANT ABNORMALITY.

Please correlate clinically and with lab. Investigations.

DR. MONICA CHHABRACONSULTANT RADIOLOGIST

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com



DIGITAL X-RAY REPORT

NAME: SHIVANGI	DATE: 27.11.2023
UHID NO: 16430	AGE: 32YRS/ SEX: F

X-RAY CHEST PA VIEW

Both the lung fields show no active parenchymal pathology.

Both the costophrenic angles are clear.

Heart size is normal.

Both the domes of diaphragm are normal.

Bony thorax appears normal.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab investigations

DR. MONICA CHHABRA

Consultant Radiologist

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019





Patient Name : Mrs.SHIVANGI
Age/Gender : 32 Y 0 M 4 D/F
UHID/MR No : SCHI.0000016430

Visit ID : SCHIOPV23380

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : fghfgjf Collected : 27/Nov/2023 09:20AM Received : 27/Nov/2023 10:19AM

Reported : 27/Nov/2023 12:48PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

PERIPHERAL SMEAR , WHOLE BLOOD EDTA

Page 1 of 12







Patient Name

: Mrs.SHIVANGI

Age/Gender

: 32 Y 0 M 4 D/F

UHID/MR No Visit ID : SCHI.0000016430

Ref Doctor

: SCHIOPV23380 : Dr.SELF

Emp/Auth/TPA ID : fghfgjf

Collected : 27/Nov/2023 09:20AM

Received : 27/Nov/2023 10:19AM Reported : 27/Nov/2023 12:48PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

HAEMOGLOBIN	11.8	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	36.10	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	3.89	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	92.8	fL	83-101	Calculated
MCH	30.4	pg	27-32	Calculated
MCHC	32.8	g/dL	31.5-34.5	Calculated
R.D.W	13.3	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	4,630	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)			•
NEUTROPHILS	53.2	%	40-80	Electrical Impedance
LYMPHOCYTES	33.2	%	20-40	Electrical Impedance
EOSINOPHILS	6.4	%	1-6	Electrical Impedance
MONOCYTES	5.9	%	2-10	Electrical Impedance
BASOPHILS	1.3	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				•
NEUTROPHILS	2463.16	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1537.16	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	296.32	Cells/cu.mm	20-500	Calculated
MONOCYTES	273.17	Cells/cu.mm	200-1000	Calculated
BASOPHILS	60.19	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	198000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOP
ERYTHROCYTE SEDIMENTATION RATE (ESR)	13	mm at the end of 1 hour	0-20	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC WITH MILD HYPOCHROMASIA.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN

Page 2 of 12







Patient Name : Mrs.SHIVANGI
Age/Gender : 32 Y 0 M 4 D/F
UHID/MR No : SCHI.0000016430

Visit ID : SCHIOPV23380

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : fghfgjf

 Collected
 : 27/Nov/2023 09:20AM

 Received
 : 27/Nov/2023 10:19AM

 Reported
 : 27/Nov/2023 04:06PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA					
BLOOD GROUP TYPE	В	Forward & Reverse Grouping with Slide/Tube Aggluti			
Rh TYPE	POSITIVE	Forward & Reverse Grouping with Slide/Tube Agglutination			

Page 3 of 12







Patient Name

: Mrs.SHIVANGI

Age/Gender

: 32 Y 0 M 4 D/F

UHID/MR No Visit ID

: SCHI.0000016430 : SCHIOPV23380

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: fghfgjf

Collected

: 27/Nov/2023 11:49AM

Received

: 27/Nov/2023 12:44PM : 27/Nov/2023 03:58PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

GLUCOSE, FASTING, NAF PLASMA	95	ma/dL	70-100	GOD - POD	
GLUCUSE, FASTING, NAF FLASIMA	93	IIIg/uL	70-100	IGOD - FOD	

Comment:

As per American Diabetes Guidelines, 2023

F			
Fasting Glucose Values in mg/dL	Interpretation		
70-100 mg/dL	Normal		
100-125 mg/dL	Prediabetes		
≥126 mg/dL	Diabetes		
<70 mg/dL	Hypoglycemia		

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2	104	mg/dL	70-140	GOD - POD
HOURS , SODIUM FLUORIDE PLASMA (2				
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 4 of 12





Ref Doctor





Method

Patient Name : Mrs.SHIVANGI

Age/Gender : 32 Y 0 M 4 D/F

UHID/MR No : SCHI.0000016430

: Dr.SELF

Test Name

Visit ID : SCHIOPV23380

Emp/Auth/TPA ID : fghfgjf

Collected : 27/Nov/2023 09:20AM

Received : 27/Nov/2023 01:16PM

Reported : 27/Nov/2023 03:35PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

Bio. Ref. Range

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Unit

Result

HBA1C, GLYCATED HEMOGLOBIN,	5.3	%	HPLC
WHOLE BLOOD EDTA			
ESTIMATED AVERAGE GLUCOSE (eAG) ,	105	mg/dL	Calculated

Comment:

WHOLE BLOOD EDTA

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

5 of 12

Page 5 of 12





Patient Name : Mrs.SHIVANGI
Age/Gender : 32 Y 0 M 4 D/F

UHID/MR No : SCHI.0000016430

Visit ID : SCHIOPV23380

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : fghfgjf Collected : 27/Nov/2023 09:20AM Received : 27/Nov/2023 10:30AM

Reported : 27/Nov/2023 12:16PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					

LIPID PROFILE, SERUM				
TOTAL CHOLESTEROL	167	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	57	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	81	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	86	mg/dL	<130	Calculated
LDL CHOLESTEROL	74.6	mg/dL	<100	Calculated
VLDL CHOLESTEROL	11.4	mg/dL	<30	Calculated
CHOL / HDL RATIO	2.06		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
III .I D1 .	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
INON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- **6.** VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 12







: Mrs.SHIVANGI Patient Name

Age/Gender : 32 Y 0 M 4 D/F

UHID/MR No : SCHI.0000016430 Visit ID : SCHIOPV23380

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : fghfgjf

Collected : 27/Nov/2023 09:20AM

Received : 27/Nov/2023 10:30AM Reported : 27/Nov/2023 12:16PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.40	mg/dL	0.20-1.20	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.20	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.20	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	16	U/L	<35	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	24.0	U/L	14-36	UV with P-5-P
ALKALINE PHOSPHATASE	64.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.90	g/dL	6.3-8.2	Biuret
ALBUMIN	4.60	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.30	g/dL	2.0-3.5	Calculated
A/G RATIO	1.39		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- · Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- · Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 12

SIN No:SE04551998





Patient Name : Mrs.SHIVANGI Age/Gender : 32 Y 0 M 4 D/F

UHID/MR No : SCHI.0000016430

Visit ID : SCHIOPV23380

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : fghfgjf Collected : 27/Nov/2023 09:20AM
Received : 27/Nov/2023 10:30AM
Reported : 27/Nov/2023 12:16PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

APCOEEMI MEDIWHEEL EIILI BODY	/ LIEAT THE ANNITAT	DI IIS CHECK	EEMALE 2DECHO E	DANINDIA EV2224
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324				
Test Name	Result	Unit	Bio. Ref. Range	Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM					
CREATININE	0.50	mg/dL	0.5-1.04	Creatinine amidohydrolase	
UREA	16.60	mg/dL	15-36	Urease	
BLOOD UREA NITROGEN	7.8	mg/dL	8.0 - 23.0	Calculated	
URIC ACID	4.70	mg/dL	2.5-6.2	Uricase	
CALCIUM	9.20	mg/dL	8.4 - 10.2	Arsenazo-III	
PHOSPHORUS, INORGANIC	4.10	mg/dL	2.5-4.5	PMA Phenol	
SODIUM	134	mmol/L	135-145	Direct ISE	
POTASSIUM	4.9	mmol/L	3.5-5.1	Direct ISE	
CHLORIDE	102	mmol/L	98 - 107	Direct ISE	

Page 8 of 12







Patient Name : Mrs.SHIVANGI Age/Gender : 32 Y 0 M 4 D/F

UHID/MR No : SCHI.0000016430

: fghfgjf

Visit ID : SCHIOPV23380 Ref Doctor : Dr.SELF

Emp/Auth/TPA ID

Collected : 27/Nov/2023 09:20AM
Received : 27/Nov/2023 10:30AM
Reported : 27/Nov/2023 11:07AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

GAMMA GLUTAMYL TRANSPEPTIDASE	13.00	U/L	12-43	Glyclyclycine
(GGT) , SERUM				Nitoranalide

Page 9 of 12







Patient Name : Mrs.SHIVANGI

Age/Gender : 32 Y 0 M 4 D/F

UHID/MR No : SCHI.0000016430

Visit ID : SCHIOPV23380

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : fghfgjf Collected : 27/Nov/2023 09:20AM

Received : 27/Nov/2023 10:29AM Reported : 27/Nov/2023 01:47PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY		DI IIS CHECK	EEMALE 2D ECHO E	DANINDIA EV2224
ARCOLEMI - MIEDIAALIEEE - LOEE BOD	I HEALTH ANNUAL	FLUS CHLCK -	TEMALE - 2D ECHO - F	AN INDIA - 1 12324
Test Name	Result	l Unit	Bio. Ref. Range	Method
10011141110	Robalt	• • • • • • • • • • • • • • • • • • • •	2.0	in o ti i o d

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM				
TRI-IODOTHYRONINE (T3, TOTAL)	0.87	ng/mL	0.67-1.81	ELFA
THYROXINE (T4, TOTAL)	6.29	μg/dL	4.66-9.32	ELFA
THYROID STIMULATING HORMONE (TSH)	2.880	μIU/mL	0.25-5.0	ELFA

Comment:

Hor pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	Т4	FT4	Conditions	
High	Low	Low	Low	rimary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis	
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.	
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism	
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy	
Low	N	N	N	Subclinical Hyperthyroidism	
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism	
Low	N	High	High	Thyroiditis, Interfering Antibodies	
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes	
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma	

Page 10 of 12







Patient Name

: Mrs.SHIVANGI

Age/Gender

: 32 Y 0 M 4 D/F

UHID/MR No

: SCHI.0000016430

Visit ID Ref Doctor : SCHIOPV23380

Emp/Auth/TPA ID

: Dr.SELF : fghfgjf Collected

: 27/Nov/2023 09:20AM

Received

: 27/Nov/2023 12:18PM : 27/Nov/2023 12:45PM

Reported : 2

Status : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

COMPLETE URINE EXAMINATION (CUE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.025		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION			•	•
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET MOUN	IT AND MICROSCOPY	•		
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	3-4	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 11 of 12







Patient Name

: Mrs.SHIVANGI

Age/Gender

: 32 Y 0 M 4 D/F

UHID/MR No

: SCHI.0000016430

Visit ID Ref Doctor : SCHIOPV23380 : Dr.SELF

Emp/Auth/TPA ID : fghfgjf

Collected : 27/Nov/2023 09:20AM

Received : 27/Nov/2023 12:18PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 27/Nov/2023 12:45PM

DEPARTMENT OF CLINICAL PATHOLOGY

Reported

ARCOFEMI - MEDIWHEEL - FULL BODY	Y HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio, Ref. Range	Method

URINE GLUCOSE(POST PRANDIAL)	NEGATIVE	NEGATIVE	Dipstick
URINE GLUCOSE(FASTING)	NEGATIVE	NEGATIVE	Dipstick

*** End Of Report ***

Result/s to Follow:

LBC PAP TEST (PAPSURE)

Dr N M.B

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist



